In this article, we will be taking a look at the 5 biggest biotechnology companies in the world. If you wish to learn about more, head straight to the 30 Biggest Biotechnology Companies in the World.
5. Argenx SE (NASDAQ:ARGX)
Market Cap: $22.02 billion
Argenx SE (NASDAQ:ARGX), based in the Netherlands, is one of the biggest biotechnology companies in the world known for its innovative immunology solutions. Their flagship therapy, efgartigimod, developed using proprietary ABDEG technology, shows promise in treating autoimmune disorders. In Q1 2024, Argenx SE (NASDAQ:ARGX) reported $1.2 billion in global net product sales for 2023 and submitted an sBLA to the FDA for VYVGART Hytrulo for CIDP, with a launch expected in mid-2024.
4. Moderna, Inc. (NASDAQ:MRNA)
Market Cap: $39.68 billion
Moderna, Inc. (NASDAQ:MRNA) is a top biotech company known for pioneering mRNA therapeutics and vaccines. Its success with Spikevax during the COVID-19 pandemic highlights its groundbreaking approach to vaccine development. With applications in infectious diseases, immuno-oncology, and more, Moderna’s mRNA technology holds vast potential. In 2023, Moderna, Inc. (NASDAQ:MRNA) reported fourth-quarter revenues of $2.8 billion, reaching $6.8 billion for the full year. It achieved a 48% market share in the U.S. retail segment during the fall 2023 COVID season, demonstrating a strong market presence.
3. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Market Cap: $105.31 billion
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), founded in 1989 in Boston, MA, is known for cystic fibrosis drugs like Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio. They also target infectious diseases, autoimmune diseases, cancer, and neurological disorders. Diversification includes Casgevy for beta-thalassemia and sickle-cell disease. In Q4 2023, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s revenue exceeded guidance by $7.9 million, reaching $154.9 million.
2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Market Cap: $105.86 billion
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the largest biotech companies that pioneers life-transforming medicines across various diseases. Founded by physician-scientists, it translates discoveries into impactful treatments. With a robust pipeline, Regeneron has FDA-approved medicines for eye diseases, cancer, and more. In 2023, revenues grew by 8% to $13.12 billion, driven by key products like Dupixent and EYLEA. Dupixent’s sales surged by 33% to $11.59 billion, while EYLEA’s U.S. sales reached $5.89 billion. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s global net sales of Libtayo rose by 50% to $869 million.
1. Novo Nordisk A/S (NYSE:NVO)
Market Cap: $447.86 billion
Novo Nordisk A/S (NYSE:NVO), stands first among the biggest biotechnology companies in the world founded in Denmark in 1923, focuses on diabetes, obesity, and rare diseases. It’s renowned for innovative medicines that significantly impact patient outcomes in diabetes care and weight loss treatments like Wegovy. Novo Nordisk A/S (NYSE:NVO) aims to expand into cardiovascular and emerging therapy areas. In 2023, its revenue reached $33.7 billion, marking a significant 31% increase over the previous year.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also take a peek at the 25 Best AI Marketing Tools for Corporations in 2024 and the 50 Cities With The Largest Population In The US.
